|
1
|
Frydrychowicz M, Kuszel Ł, Dworacki G and
Budna-Tukan J: MicroRNA in lung cancer-a novel potential way for
early diagnosis and therapy. J Appl Genet. 64:459–477. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Juang YR, Ang L and Seow WJ: Predictive
performance of risk prediction models for lung cancer incidence in
Western and Asian countries: A systematic review and meta-analysis.
Sci Rep. 15:42592025. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang M and Ma C: LSR promotes cell
proliferation and invasion in lung cancer. Comput Math Methods Med.
2021:66519072021.PubMed/NCBI
|
|
4
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
5
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33.
2021.PubMed/NCBI
|
|
6
|
Pallis AG and Syrigos KN: Lung cancer in
never smokers: Disease characteristics and risk factors. Crit Rev
Oncol Hematol. 88:494–503. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jones GS and Baldwin DR: Recent advances
in the management of lung cancer. Clin Med (Lond). 18 (Suppl
2):S41–S46. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lim RB: End-of-life care in patients with
advanced lung cancer. Ther Adv Respir Dis. 10:455–467. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koh YC, Ho CT and Pan MH: Recent advances
in cancer chemoprevention with phytochemicals. J Food Drug Anal.
28:14–37. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bade BC and Dela Cruz CS: Lung cancer
2020: Epidemiology, etiology, and prevention. Clin Chest Med.
41:1–24. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Similie D, Minda D, Bora L, Kroškins V,
Lugiņina J, Turks M, Dehelean CA and Danciu C: An update on
pentacyclic triterpenoids ursolic and oleanolic acids and related
derivatives as anticancer candidates. Antioxidants (Basel).
13:9522024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pironi AM, de Araújo PR, Fernandes MA,
Salgado HRN and Chorilli M: Characteristics, biological properties
and analytical methods of ursolic acid: A review. Crit Rev Anal
Chem. 48:86–93. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mlala S, Oyedeji AO, Gondwe M and Oyedeji
OO: Ursolic acid and its derivatives as bioactive agents.
Molecules. 24:27512019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kashyap D, Sharma A, Tuli HS, Punia S and
Sharma AK: Ursolic acid and oleanolic acid: Pentacyclic terpenoids
with promising Anti-inflammatory activities. Recent Pat Inflamm
Allergy Drug Discov. 10:21–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liobikas J, Majiene D, Trumbeckaite S,
Kursvietiene L, Masteikova R, Kopustinskiene DM, Savickas A and
Bernatoniene J: Uncoupling and antioxidant effects of ursolic acid
in isolated rat heart mitochondria. J Nat Prod. 74:1640–1644. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jayaprakasam B, Olson LK, Schutzki RE, Tai
MH and Nair MG: Amelioration of obesity and glucose intolerance in
high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in
Cornelian cherry (Cornus mas). J Agric Food Chem. 54:243–248. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu SG, Zhang CJ, Xu XE, Sun JH, Zhang L
and Yu PF: Ursolic acid derivative ameliorates
Streptozotocin-induced diabestic bone deleterious effects in mice.
Int J Clin Exp Pathol. 8:3681–3690. 2015.PubMed/NCBI
|
|
18
|
Sundaresan A, Radhiga T and Pugalendi KV:
Effect of ursolic acid and Rosiglitazone combination on hepatic
lipid accumulation in high fat diet-fed C57BL/6J mice. Eur J
Pharmacol. 741:297–303. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Erdmann J, Kujaciński M and Wiciński M:
Beneficial effects of ursolic acid and its derivatives-focus on
potential biochemical mechanisms in cardiovascular conditions.
Nutrients. 13:39002021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shi Y, Leng Y, Liu D, Liu X, Ren Y, Zhang
J and Chen F: Research advances in protective effects of ursolic
acid and oleanolic acid against gastrointestinal diseases. Am J
Chin Med. 49:413–435. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen C, Ai Q, Shi A, Wang N, Wang L and
Wei Y: Oleanolic acid and ursolic acid: Therapeutic potential in
neurodegenerative diseases, neuropsychiatric diseases and other
brain disorders. Nutr Neurosci. 26:414–428. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sandhu SS, Rouz SK, Kumar S, Swamy N,
Deshmukh L, Hussain A, Haque S and Tuli HS: Ursolic acid: A
pentacyclic triterpenoid that exhibits anticancer therapeutic
potential by modulating multiple oncogenic targets. Biotechnol
Genet Eng Rev. 39:729–759. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iqbal J, Abbasi BA, Ahmad R, Mahmood T,
Kanwal S, Ali B, Khalil AT, Shah SA, Alam MM and Badshahet H:
Ursolic acid a promising candidate in the therapeutics of breast
cancer: Current status and future implications. Biomed
Pharmacother. 108:752–756. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin JH, Xu JJ, Liu XF, Liu WH, Wang YF, Li
ZS, Wang LW and Wang W: Ursolic acid promotes apoptosis, autophagy,
and chemosensitivity in gemcitabine-resistant human pancreatic
cancer cells. Phytother Res. 34:2053–2066. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Meng Y, Lin ZM, Ge N, Zhang DL, Huang J
and Kong F: Ursolic acid induces apoptosis of prostate cancer cells
via the PI3K/Akt/mTOR pathway. Am J Chin Med. 43:1471–1486. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang H, Zhang X, Ma X and Wang X: Ursolic
acid in colorectal cancer: Mechanisms, current status, challenges,
and future research directions. Pharmacol Rep. 77:72–86. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo JL, Han T, Bao L, Li XM, Ma JQ and
Tang LP: Ursolic acid promotes the apoptosis of cervical cancer
cells by regulating endoplasmic reticulum stress. J Obstet Gynaecol
Res. 45:877–881. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cai C, Zhi Y, Xie C, Geng S, Sun F, Ji Z,
Zhang P, Wang H and Tang J: Ursolic acid-downregulated long
noncoding RNA ASMTL-AS1 inhibits renal cell carcinoma growth via
binding to HuR and reducing vascular endothelial growth factor
expression. J Biochem Mol Toxicol. 37:e233892023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Namdeo P, Gidwani B, Tiwari S, Jain V,
Joshi V, Shukla SS, Pandey RK and Vyas A: Therapeutic potential and
novel formulations of ursolic acid and its derivatives: An updated
review. J Sci Food Agric. 103:4275–4292. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ma X, Bai Y, Liu K, Han Y, Zhang J, Liu Y,
Hou X, Hao E, Hou Y and Bai G: Ursolic acid inhibits the
cholesterol biosynthesis and alleviates high fat Diet-induced
hypercholesterolemia via irreversible inhibition of HMGCS1 in vivo.
Phytomedicine. 103:1542332022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fernández-Hernández A, Martinez A, Rivas
F, García-Mesa JA and Parra A: Effect of the solvent and the sample
preparation on the determination of triterpene compounds in
two-phase olive-mill-waste samples. J Agric Food Chem.
63:4269–4275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu J: Pharmacology of oleanolic acid and
ursolic acid. J Ethnopharmacol. 49:57–68. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ikeda Y, Murakami A and Ohigashi H:
Ursolic acid: An anti- and pro-inflammatory triterpenoid. Mol Nutr
Food Res. 52:26–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang X, Xiong W, Wang X, Qin L, Zhong M,
Liu Y, Xiong Y, Yi X, Wang X and Zhang H: Ursolic acid attenuates
cholestasis through NRF2-mediated regulation of UGT2B7 and
BSEP/MRP2. Naunyn Schmiedebergs Arch Pharmacol. 397:2257–2267.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luan M, Wang H, Wang J, Zhang X, Zhao F,
Liu Z and Meng Q: Advances in Anti-inflammatory activity, mechanism
and therapeutic application of ursolic acid. Mini Rev Med Chem.
22:422–436. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shanmugam MK, Dai X, Kumar AP, Tan BK,
Sethi G and Bishayee A: Ursolic acid in cancer prevention and
treatment: Molecular targets, pharmacokinetics and clinical
studies. Biochem Pharmacol. 85:1579–1587. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Khwaza V, Oyedeji OO and Aderibigbe BA:
Ursolic Acid-based derivatives as potential anti-cancer agents: An
update. Int J Mol Sci. 21:59202020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kang DY, Sp N, Jang KJ, Jo ES, Bae SW and
Yang YM: Antitumor effects of natural bioactive ursolic acid in
embryonic cancer stem cells. J Oncol. 2022:67372482022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang S, Chang X, Zhang J, Li J, Wang N,
Yang B, Pan B, Zheng Y, Wang X, Ou H and Wang Z: Ursolic acid
inhibits breast cancer metastasis by suppressing glycolytic
metabolism via activating SP1/Caveolin-1 signaling. Front Oncol.
11:7455842021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Panda SS, Thangaraju M and Lokeshwar BL:
Ursolic acid analogs as potential therapeutics for cancer.
Molecules. 27:89812022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang N, Liu S, Shi S, Chen Y, Xu F, Wei X
and Xu Y: Solubilization and delivery of Ursolic-acid for
modulating tumor microenvironment and regulatory T cell activities
in cancer immunotherapy. J Control Release. 320:168–178. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen H, Gao Y, Wang A, Zhou X, Zheng Y and
Zhou J: Evolution in medicinal chemistry of ursolic acid
derivatives as anticancer agents. Eur J Med Chem. 92:648–655. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jiang H, Wei JH, Lin CY, Liang GB, He RJ,
Huang RZ, Ma XL, Huang GB and Zhang Y: Ursolic
acid-piperazine-dithiocarbamate ruthenium(II) polypyridyl complexes
induced necroptosis in MGC-803 cells. Metallomics. 14:mfac0722022.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kim JH, Kim YH, Song GY, Kim DE, Jeong YJ,
Liu KH, Chung YH and Oh S: Ursolic acid and its natural derivative
corosolic acid suppress the proliferation of APC-mutated colon
cancer cells through promotion of beta-catenin degradation. Food
Chem Toxicol. 67:87–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gou W, Luo N, Wei H, Wu H, Yu X, Duan Y,
Bi C, Ning H, Hou W and Li Y: Ursolic acid derivative UA232 evokes
apoptosis of lung cancer cells induced by endoplasmic reticulum
stress. Pharm Biol. 58:707–715. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sun L, Li B, Su X, Chen G, Li Y, Yu L, Li
L and Wei W: An ursolic acid derived small molecule triggers cancer
cell death through hyperstimulation of macropinocytosis. J Med
Chem. 60:6638–6648. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu X, Qi M, Li X, Wang J and Wang M:
Curcumin: A natural organic component that plays a Multi-faceted
role in ovarian cancer. J Ovarian Res. 16:472023. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nedopekina DA, Gubaidullin RR, Odinokov
VN, Maximchik PV, Zhivotovsky B, Bel'skii YP, Khazanov VA,
Manuylova AV, Gogvadze V and Spivak AY: Mitochondria-targeted
betulinic and ursolic acid derivatives: Synthesis and anticancer
activity. Medchemcomm. 8:1934–1945. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Way TD, Tsai SJ, Wang CM, Ho CT and Chou
CH: Chemical constituents of Rhododendron formosanum show
pronounced growth inhibitory effect on non-small-cell lung
carcinoma cells. J Agric Food Chem. 62:875–884. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Abdel-Hamid NM and Abass SA: Matrix
metalloproteinase contribution in management of cancer
proliferation, metastasis and drug targeting. Mol Biol Rep.
48:6525–6538. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lai MY, Leung HW, Yang WH, Chen WH and Lee
HZ: Up-regulation of matrix metalloproteinase family gene
involvement in ursolic acid-induced human lung non-small carcinoma
cell apoptosis. Anticancer Res. 27:145–153. 2007.PubMed/NCBI
|
|
52
|
Kang DY, Sp N, Lee JM and Jang KJ:
Antitumor effects of ursolic acid through mediating the inhibition
of STAT3/PD-L1 signaling in Non-small cell lung cancer cells.
Biomedicines. 9:2972021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Nunnari J and Suomalainen A: Mitochondria:
In sickness and in health. Cell. 148:1145–1159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chen CJ, Shih YL, Yeh MY, Liao NC, Chung
HY, Liu KL, Lee MH, Chou PY, Hou HY, Chou JS and Chung JG: Ursolic
acid induces apoptotic cell death through AIF and endo G release
through a Mitochondria-dependent pathway in NCI-H292 human lung
cancer cells in vitro. In Vivo. 33:383–391. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ma T, Zhou J, Li J and Chen Q: Hyaluronic
Acid-modified liposomes for ursolic Acid-targeted delivery treat
lung cancer based on p53/ARTS-mediated mitochondrial apoptosis.
Iran J Pharm Res. 22:e1317582023. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Castrejón-Jiménez NS, Leyva-Paredes K,
Baltierra-Uribe SL, Castillo-Cruz J, Campillo-Navarro M,
Hernández-Pérez AD, Luna-Angulo AB, Chacón-Salinas R, Coral-Vázquez
RM, Estrada-García I, et al: Ursolic and oleanolic acids induce
mitophagy in A549 human lung cancer cells. Molecules. 24:34441019.
View Article : Google Scholar
|
|
57
|
Song B, Zhang Q, Yu M, Qi X, Wang G, Xiao
L, Yi Q and Jin W: Ursolic acid sensitizes radioresistant NSCLC
cells expressing HIF-1α through reducing endogenous GSH and
inhibiting HIF-1α. Oncol Lett. 13:754–762. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Smith G, Alholm Z, Coleman RL and Monk BJ:
DNA damage repair Inhibitors-combination therapies. Cancer J.
27:501–505. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wang JY: DNA damage and apoptosis. Cell
Death Differ. 8:1047–1048. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kaina B: DNA damage-triggered apoptosis:
Critical role of DNA repair, double-strand breaks, cell
proliferation and signaling. Biochem Pharmacol. 66:1547–1554. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Campillo-Marcos I, García-González R,
Navarro-Carrasco E and Lazo PA: The human VRK1 chromatin kinase in
cancer biology. Cancer Lett. 503:117–128. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kim SH, Ryu HG, Lee J, Shin J, Harikishore
A, Jung HY, Kim YS, Lyu HN, Oh E, Baek NI, et al: Ursolic acid
exerts anti-cancer activity by suppressing Vaccinia-related kinase
1-mediated damage repair in lung cancer cells. Sci Rep.
5:145702015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Han T, Kang D, Ji D, Wang X, Zhan W, Fu M,
Xin HB and Wang JB: How does cancer cell metabolism affect tumor
migration and invasion? Cell Adh Migr. 7:395–403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Affara NI, Andreu P and Coussens LM:
Delineating protease functions during cancer development. Methods
Mol Biol. 539:1–32. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Liu J: Oleanolic acid and ursolic acid:
Research perspectives. J Ethnopharmacol. 100:92–94. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Xu F, Li M, Que Z, Su M, Yao W, Zhang Y,
Luo B, Li Y, Zhang Z and Tian J: Combined chemo-immuno-photothermal
therapy based on ursolic acid/astragaloside IV-loaded hyaluronic
acid-modified polydopamine nanomedicine inhibiting the growth and
metastasis of non-small cell lung cancer. J Mater Chem B.
11:3453–3472. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Huang CY, Lin CY, Tsai CW and Yin MC:
Inhibition of cell proliferation, invasion and migration by ursolic
acid in human lung cancer cell lines. Toxicol In Vitro.
25:1274–1280. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Ruan JS, Zhou H, Yang L, Wang L, Jiang ZS,
Sun H and Wang SM: Ursolic acid attenuates TGF-β1-induced
epithelial-mesenchymal transition in NSCLC by targeting integrin
αVβ5/MMPs signaling. Oncol Res. 27:593–600. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Liu K, Guo L, Miao L, Bao W, Yang J, Li X,
Xi T and Zhao W: Ursolic acid inhibits epithelial-mesenchymal
transition by suppressing the expression of astrocyte-elevated
gene-1 in human nonsmall cell lung cancer A549 cells. Anticancer
Drugs. 24:494–503. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Jesudason EC, Connell MG, Fernig DG, Lloyd
DA and Losty PD: Cell proliferation and apoptosis in experimental
lung hypoplasia. J Pediatr Surg. 35:129–133. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yang K, Chen Y, Zhou J, Ma L, Shan Y,
Cheng X, Wang Y, Zhang Z, Ji X, Chen L, et al: Ursolic acid
promotes apoptosis and mediates transcriptional suppression of
CT45A2 gene expression in non-small-cell lung carcinoma harbouring
EGFR T790M mutations. Br J Pharmacol. 176:4609–4624. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Changotra H, Kaur S, Yadav SS, Gupta GL,
Parkash J and Duseja A: ATG5: A central autophagy regulator
implicated in various human diseases. Cell Biochem Funct.
40:650–667. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Baeva ME and Camara-Lemarroy C: The role
of autophagy protein Atg5 in multiple sclerosis. Mult Scler Relat
Disord. 79:1050292023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wang M, Yu H, Wu R, Chen ZY, Hu Q, Zhang
YF, Gao SH and Zhou GB: Autophagy inhibition enhances the
inhibitory effects of ursolic acid on lung cancer cells. Int J Mol
Med. 46:1816–1826. 2020.PubMed/NCBI
|
|
76
|
Wu J, Zhao S, Tang Q, Zheng F, Chen Y,
Yang L, Yang X, Li L, Wu W and Hann SS: Activation of SAPK/JNK
mediated the inhibition and reciprocal interaction of DNA
methyltransferase 1 and EZH2 by ursolic acid in human lung cancer
cells. J Exp Clin Cancer Res. 34:992015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Higgins MJ and Ettinger DS: Chemotherapy
for lung cancer: The state of the art in 2009. Expert Rev
Anticancer Ther. 9:1365–1378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Souhami RL: Defining the role of
chemotherapy in non-small-cell lung cancer. Ann Oncol. 6:317–318.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wu T, Yan D, Hou W, Jiang H, Wu M, Wang Y,
Chen G, Tang C, Wang Y and Xu H: Biomimetic red blood cell
membrane-Mediated nanodrugs loading ursolic acid for targeting
NSCLC therapy. Cancers (Basel). 14:45202022. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Shen M, Xu Z, Xu W, Jiang K, Zhang F, Ding
Q, Xu Z and Chen Y: Inhibition of ATM reverses EMT and decreases
metastatic potential of cisplatin-resistant lung cancer cells
through JAK/STAT3/PD-L1 pathway. J Exp Clin Cancer Res. 38:1492019.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Fan L, Wang X, Cheng C, Wang S, Li X, Cui
J, Zhang B and Shi L: Inhibitory effect and mechanism of ursolic
acid on Cisplatin-induced resistance and stemness in human lung
cancer A549 cells. Evid Based Complement Alternat Med.
2023:13073232023. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Li S, Guo X, Liu H, Chen Y, Wan H, Kang X,
Qin J and Guo S: Ursolic acid, an inhibitor of TMEM16A, co-loaded
with cisplatin in hydrogel drug delivery system for multi-targeted
therapy of lung cancer. Int J Biol Macromol. 277:1345872024.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Chen Q, Luo J, Wu C, Lu H, Cai S, Bao C,
Liu D and Kong J: The miRNA-149-5p/MyD88 axis is responsible for
ursolic Acid-mediated attenuation of the stemness and
chemoresistance of non-small cell lung cancer cells. Environ
Toxicol. 35:561–569. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Pérez-Herrero E and Fernández-Medarde A:
Advanced targeted therapies in cancer: Drug nanocarriers, the
future of chemotherapy. Eur J Pharm Biopharm. 93:52–79. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Fu S, Li G, Zang W, Zhou X, Shi K and Zhai
Y: Pure drug Nano-assemblies: A facile carrier-free nanoplatform
for efficient cancer therapy. Acta Pharm Sin B. 12:92–106. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Jinhua W: Ursolic acid: Pharmacokinetics
process in vitro and in vivo, a mini review. Arch Pharm (Weinheim).
352:e18002222019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Antonio E, Dos Reis Antunes Junior O,
Marcano RGDJV, Diedrich C, da Silva Santos J, Machado CS, Khalil NM
and Mainardes RM: Chitosan modified poly (lactic acid)
nanoparticles increased the ursolic acid oral bioavailability. Int
J Biol Macromol. 172:133–142. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Yang L, Sun Z, Zu Y, Zhao C, Sun X, Zhang
Z and Zhang L: Physicochemical properties and oral bioavailability
of ursolic acid nanoparticles using supercritical anti-solvent
(SAS) process. Food Chem. 132:319–325. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Yu D, Kan Z, Shan F, Zang J and Zhou J:
Triple strategies to improve oral bioavailability by fabricating
coamorphous forms of ursolic acid with piperine: Enhancing
Water-solubility, permeability, and inhibiting cytochrome P450
isozymes. Mol Pharm. 17:4443–4462. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Chen Q, Luo S, Zhang Y and Chen Z:
Development of a liquid chromatography-mass spectrometry method for
the determination of ursolic acid in rat plasma and tissue:
Application to the pharmacokinetic and tissue distribution study.
Anal Bioanal Chem. 399:2877–2884. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Wang M, Zhao T, Liu Y, Wang Q, Xing S, Li
L, Wang L, Liu L and Gao D: Ursolic acid liposomes with chitosan
modification: Promising antitumor drug delivery and efficacy. Mater
Sci Eng C Mater Biol Appl. 71:1231–1240. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Lei P, Li Z, Hua Q, Song P, Gao L, Zhou L
and Cai Q: Ursolic acid alleviates neuroinflammation after
intracerebral hemorrhage by mediating microglial pyroptosis via the
NF-κB/NLRP3/GSDMD pathway. Int J Mol Sci. 24:147712023. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Sun K, Wu H, Zhu Q, Gu K, Wei H, Wang S,
Li L, Wu C, Chen R, Pang Y, et al: Global landscape and trends in
lifetime risks of haematologic malignancies in 185 countries:
Population-based estimates from GLOBOCAN 2022. EClinicalMedicine.
83:1031932025. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
95
|
Wu BY and Parks LM: Chemical studies on
ursolic acid. J Am Pharm Assoc Am Pharm Assoc. 42:603–606. 1953.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Ram Kumar Pandian S, Kunjiappan S, Pavadai
P, Sundarapandian V, Chandramohan V and Sundar K: Delivery of
ursolic acid by polyhydroxybutyrate nanoparticles for cancer
therapy: In silico and in vitro studies. Drug Res (Stuttg).
72:72–81. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Sharma R, Yadav V, Jha S, Dighe S and Jain
S: Unveiling the potential of ursolic acid modified hyaluronate
nanoparticles for combination drug therapy in triple negative
breast cancer. Carbohydr Polym. 338:1221962024. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
O'Malley M, King AN, Conte M, Ellingrod VL
and Ramnath N: Effects of cigarette smoking on metabolism and
effectiveness of systemic therapy for lung cancer. J Thorac Oncol.
9:917–926. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Zevin S and Benowitz NL: Drug interactions
with tobacco smoking. An update. Clin Pharmacokinet. 36:425–438.
1999. View Article : Google Scholar : PubMed/NCBI
|
